BCAL Diagnostics Future Growth
Future criteria checks 5/6
BCAL Diagnostics is forecast to grow earnings and revenue by 90.6% and 77.6% per annum respectively while EPS is expected to grow by 99.2% per annum.
Key information
90.6%
Earnings growth rate
99.2%
EPS growth rate
| Biotechs earnings growth | 15.3% |
| Revenue growth rate | 77.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Aug 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2026 | 12 | 4 | 4 | 4 | 1 |
| 6/30/2025 | 3 | -7 | -7 | -7 | 1 |
| 6/30/2024 | 3 | -6 | -6 | -5 | N/A |
| 3/31/2024 | 3 | -6 | -5 | -4 | N/A |
| 12/31/2023 | 4 | -5 | -5 | -4 | N/A |
| 9/30/2023 | 3 | -5 | -6 | -5 | N/A |
| 6/30/2023 | 3 | -5 | -6 | -6 | N/A |
| 3/31/2023 | 2 | -5 | -6 | -5 | N/A |
| 12/31/2022 | 1 | -5 | -5 | -5 | N/A |
| 9/30/2022 | 1 | -4 | -4 | -4 | N/A |
| 6/30/2022 | 1 | -3 | -3 | -3 | N/A |
| 3/31/2022 | 1 | -3 | -3 | -3 | N/A |
| 12/31/2021 | 1 | -3 | -3 | -3 | N/A |
| 9/30/2021 | 0 | -2 | -2 | -2 | N/A |
| 6/30/2021 | 0 | -2 | -1 | -1 | N/A |
| 3/31/2021 | 0 | -1 | -1 | -1 | N/A |
| 12/31/2020 | 1 | 0 | 0 | 0 | N/A |
| 9/30/2020 | 0 | -1 | 0 | 0 | N/A |
| 6/30/2020 | 0 | -1 | -1 | -1 | N/A |
| 6/30/2019 | 0 | 0 | -1 | -1 | N/A |
| 6/30/2018 | 0 | 0 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: BDX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BDX is expected to become profitable in the next 3 years.
Revenue vs Market: BDX's revenue (77.6% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: BDX's revenue (77.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BDX's Return on Equity is forecast to be high in 3 years time